Drug Approval | August 30, 2024
Natco Pharma announces submission of TABRECTA to USFDA
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
The emergence of new infections in India is a growing concern
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Our centers are performing as expected or even better
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Subscribe To Our Newsletter & Stay Updated
